Loading ...

With the market for GLP-1 weight-loss drugs increasing rapidly, consumer apps that send reminders, track progress, and explain side effects, are emerging. While there are no data on the number of currently available apps, users are likely in the millions, and counting, as new apps continue to surface.

Among the more popular apps that release user data (and many don’t) are MeAgain, a GLP-1 progress tracker that reports having over 372,000 registered users, and Shotsy, which reports having more than 250,000 active users monthly.

Established nutrition and weight-loss apps are also adding GLP-1-specific platforms. For example, MyNetDiary, said to be a top-rated calorie counter and nutrition tracking app with 31 million registered users, recently launched GLP-1 Companion for its Premium tier members.

On the clinical side, GLP-1 apps such as Omada Health’s GLP-1 Care Track (used by more than 150,000 members) and Voy (used by 85,000+ members) pair behavioral coaching with pharmacotherapy and have been shown to improve outcomes — but they are only available via health plan or employer benefits.

Together, consumer and clinical apps represent a fast-moving, commercially driven attempt to fill a real gap: Many patients on GLP-1s receive a prescription and little else in the way of ongoing support. The aim is to boost adherence and persistence, against a backdrop of data showing that among patients newly prescribed GLP-1s for obesity, 90% either never started therapy or dropped off within a year.

Consumer Apps Useful, but Not Evidence-Based

Consumer apps are appealing largely because they’re practical. As one GLAPP user put it, “Being able to enter custom doses, exact shot times, and see drug concentration levels in my body has completely changed how I manage dosing and side effects.”

A MeAgain user commented, “Reviewing my shot locations has helped me remember to rotate locations.”

But do clinicians think they’re helpful? “Probably yes, in a limited and practical sense, but with important caveats,” Fatima Cody Stanford, MD, MPH, MPA, MBA, an obesity medicine physician at Massachusetts General Hospital and associate professor at Harvard Medical School, Boston, told Medscape Medical News. “These apps are designed to help users stay consistent, confident, and organized during GLP-1 treatment by handling logistics such as injection-day reminders, dose changes, side-effect tracking, and progress monitoring. The features they offer address real pain points that patients report, particularly around adherence and the cognitive burden of managing a complex titration schedule.”

However, none of these apps have been tested in randomized controlled trials, and the broader mHealth literature suggests that their benefits depend heavily on sustained engagement, she said.

Furthermore, she added, “consumer apps displaying features such as estimated medication level charts often use simplified pharmacokinetic formulas (eg, assuming peak concentration at 24 hours with 80% bioavailability) without disclosing their methodology, potentially making some data visualizations unreliable or misleading to patients. The apps should be considered adherence and organizational tools, not clinical decision support.”

Rekha Kumar, MD, an endocrinologist and obesity medicine expert at Weill Cornell Medicine, New York City, agreed, noting, “‘Helpful’ and ‘evidence-based’ are not the same thing, and right now we simply don’t have the clinical data to say these tools move the needle on weight loss, metabolic markers, or safety. Until we do, I’d categorize them as potentially useful organizational tools, not therapeutic interventions.”

Privacy, Anxiety Concerns

“The question is not so much whether the apps are good or bad, but whether they are being used appropriately, proportionately, and with adequate safeguards,” Austen El-Osta, PhD, MSc, director of the Self-Care Academic Research Unit at the School of Public Health at Imperial College London, London, England, told Medscape Medical News.

Issues to consider include: How did the patient find the app? What data is it collecting, and who is the data shared with? Is there any independent quality assurance? “There’s always informatics data that’s collected,” he said. “So if the right locks and keys aren’t there, people may unknowingly be giving implied consent or manufactured consent to give away a lot of their data to a third party.”

These privacy risks are “real,” Stanford affirmed. “Consumer apps, unlike clinical platforms, are generally not HIPAA [Health Insurance Portability and Accountability Act]-covered entities. Clinicians should advise patients to read privacy policies carefully before sharing health data.”

Raising anxiety is another risk. “Many GLP-1 apps track not only dosage but also user moods, cravings, and lifestyle choices and use subtle design choices such as celebratory notifications, streak counters, and accountability reminders, borrowed from social-media psychology,” she said. “For some users, this fosters motivation; for others, it fuels anxiety and dependency. Clinicians should check in with patients about whether tracking is helping or creating an unhealthy fixation.”

El-Osta agreed. “Some people will constantly [be] self-monitoring, wondering ‘Am I taking enough of the drug?’ ‘Am I losing weight fast enough?’ There’s constant anxiety about maybe not doing well enough, quickly enough,” Also, some consumer apps offer personalized advice that may not be quality-assured, he said. “And of course, there’s always the risk of someone thinking that the app will replace a clinician or the healthcare professional or the health system.”

Clinical Apps More Rigorous, Less Accessible

Clinical-grade platforms that provide companion apps are different from consumer apps, in that these validated digital therapeutics are backed by peer-reviewed studies and often are embedded in structured support programs.

The emerging evidence is encouraging. Omada Health’s Enhanced GLP-1 Care Track reported 94% persistence through 12 weeks and 84% through 24 weeks — higher than the 42%-74% range seen in real-world studies.

El-Osta, who is also chair of the Research Trailblazers Group, a Global Expert Mission on Digital Health Technologies with Innovate UK, was principal author of a recent retrospective study of the Voy digital weight management platform. Researchers found that digitally engaged patients who completed coaching sessions, logged weight regularly, and used the in-app features were more likely to achieve 5% or greater weight loss than nonengaged participants, and use of the digital therapeutic enhanced weight-loss outcomes by as much as 53% at month 4.

“These apps are materially different from consumer wellness apps in that they’ve been evaluated properly,” El-Osta said. “However, they are largely locked behind specific payer relationships, employer benefits, or health system memberships, making them unavailable to the majority of patients taking GLP-1s in the real world. That’s a meaningful equity gap.”

Knowledge Gaps Persist

Despite the commercial momentum and some encouraging real-world data for clinical-grade digital therapeutics, rigorous evidence for GLP-1 companion apps remains thin. “We need prospective, controlled data showing whether any of these consumer apps actually improve clinically meaningful outcomes, not just engagement metrics or user satisfaction scores,” Kumar said.

“Specifically, we need studies examining adherence rates, side-effect management, and discontinuation rates in app users vs nonusers, ideally stratified by access to concurrent clinical support,” she added.

Stanford pointed to additional areas of concern. “There’s essentially no published evidence on the effects of apps on nutritional adequacy — a particular concern, since GLP-1 patients are at risk for muscle loss and protein/micronutrient deficiencies,” she said. “Extended follow-up periods and objective measures of adherence and adverse events are critical for a comprehensive understanding of long-term benefits and risks in this space.”

El-Osta called for rigorous assessments instead of ratings and testimonials. “We need independent peer-reviewed evaluation rather than relying on what people are saying,” he said. “We haven’t seen a high-impact, high-visibility trial on digital health therapeutics for GLP-1 with, say, one of the top 10 universities in the world.”

He also stressed the need for research that accounts for the full range of users. “There are different typologies — no one-size-fits-all.” In addition, it’s important to assess outcomes of users who use the app from the outset, when they first get their medication, and those who start using the app later.

Stanford noted that the market’s rapid pace adds another layer of uncertainty: “Most consumer apps are built by small teams, sometimes by patients themselves, without clinical oversight. Features and pricing can change rapidly. Clinicians don’t need to vet specific apps, but staying broadly aware of what patients are using, and asking about it, is increasingly important.”

What to Tell Patients Now

Even given the caveats and concerns, those interviewed felt that self-monitoring likely has more upsides than downsides. “Self-monitoring is reasonable to recommend, especially given how many patients have limited clinical contact,” Stanford said. Logging nausea, constipation, and energy levels, for example, can help clinicians spot triggers and adjust treatment. Therefore, patients should be advised to bring their apps to appointments.

“Patients on GLP-1s also need clinical support and recommending an app without that infrastructure risks giving both the patient and the prescriber a false sense of security,” Kumar warned. “The message to patients should be, ‘Use these tools as a supplement to care, not a substitute for it.’”

El-Osta noted that the apps’ strongest contribution may be to health literacy — helping patients understand why slow dose titration matters, what side effects to watch for, and how nutrition needs shift when appetite is suppressed.

As for the message, he added, “Clinicians should say that self-care does not mean no care; you can’t just ignore the clinician and not go back. And these medications are not passive therapies. They often require behavioral change, and at the least, an app could help nudge you in the right direction.”

Kumar disclosed that Found Health, where she reported serving as senior medical advisor, is a metabolic health telehealth company. She reported not being employed by a GLP-1 app company. Stanford and El-Osta reported having no relevant conflicts of interest.

Marilynn Larkin, MA, is an award-winning medical writer and editor whose work has appeared in numerous publications, including Medscape Medical News and its sister publication MDedge, The Lancet (where she was a contributing editor), and Reuters Health.